Shaomeng Wang is a Chinese-American chemist currently the Warner-Lambert/Parke-Davis Professor in Medicine at University of Michigan and a former Co-Editor-in-Chief at American Chemical Society's Journal of Medicinal Chemistry. A cited expert in his field, his interests are synthesis and design of moleculars, neurological diseases and computational and informatics. He was Elected as Fellow at the National Academy of Inventors in 2014. Dr. Wang was named to the AAAS Fellows Section on Pharmaceutical Sciences in 2019, and is the recipient of the Division of Medicinal Chemistry Award 2020 American Chemical Society.
Education He earned his B.S. in Chemistry at Peking University and his Ph.D at Case Western Reserve University. He later began teaching at Georgetown University and University of Michigan Medical School.
Publications Comparative evaluation of 11 scoring functions for molecular docking, Renxiao Wang, Yipin Lu, Shaomeng Wang, Journal of medicinal chemistry, 2003 Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition, Proceedings of the National Academy of Sciences, 2008 Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2− p53 interaction, Journal of medicinal chemistry, 2006 The PDBbind database: Collection of binding affinities for protein− ligand complexes with known three-dimensional structures, Journal of medicinal chemistry, 2004 Structure-based design of potent non-peptide MDM2 inhibitors, Journal of the American Chemical Society, 2005 Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy, Annual review of pharmacology and toxicology, 2009 A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells, Hui Song, Renxiao Wang, Shaomeng Wang, Jiayuh Lin, Proceedings of the National academy of Sciences of the United States of America, 2005 Compounds developed by Shaomeng Wang Flazalone TW-37Shaomeng Wang, et al. WO2006023778 (University of Michigan). CJ-998Shaomeng Wang, et al. WO2010025235 (University of Michigan). Hydroxycoumarin tetramerZhao, He; Neamati, Nouri; Hong, Huixiao; Mazumder, Abhijit; Wang, Shaomeng; Sunder, Sanjay; Milne, George W. A.; Pommier, Yves; Burke, Terrence R. (1997). "Coumarin-Based Inhibitors of HIV Integrase". Journal of Medicinal Chemistry. 40 (2): 242–249. doi:10.1021/jm960450v.Mazumder, Abhijit; Wang, Shaomeng; Neamati, Nouri; Nicklaus, Marc; Sunder, Sanjay; Chen, Julie; Milne, George W. A.; Rice, William G.; Burke,, Terrence R.; Pommier, Yves (1996). "Antiretroviral Agents as Inhibitors of both Human Immunodeficiency Virus Type 1 Integrase and Protease". Journal of Medicinal Chemistry. 39 (13): 2472–2481. doi:10.1021/jm960074e. CJ-1882Chen, Jianyong; Levant, Beth; Jiang, Cheng; Keck, Thomas M.; Newman, Amy Hauck; Wang, Shaomeng (2014). "Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D3 Receptor Antagonists". Journal of Medicinal Chemistry. 57 (11): 4962–4968. doi:10.1021/jm401798r
References